Cleared Traditional

K181861 - Embrace (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K181861 · Empatica S.R.L. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2018
Decision
161d
Days
Class 2
Risk

K181861 is an FDA 510(k) clearance for the Embrace. Classified as Physiological Signal Based Seizure Monitoring System (product code POS), Class II - Special Controls.

Submitted by Empatica S.R.L. (Milano, IT). The FDA issued a Cleared decision on December 20, 2018 after a review of 161 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1580 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Empatica S.R.L. devices

Submission Details

510(k) Number K181861 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 12, 2018
Decision Date December 20, 2018
Days to Decision 161 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
13d slower than avg
Panel avg: 148d · This submission: 161d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code POS Physiological Signal Based Seizure Monitoring System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1580
Definition The Physiological Signal Based Seizure Monitoring System Is A Prescription Device That Uses Physiological Signal To Identify Abnormal Physiological Activity That May Be Associated With A Seizure. The System Does Not Predict Seizure Onsets, And Is Not Intended As A Standalone Seizure Monitoring Device.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - POS Physiological Signal Based Seizure Monitoring System

All 9
Devices cleared under the same product code (POS) and FDA review panel - the closest regulatory comparables to K181861.
Nelli (Version 7.11)
K251506 · Neuro Event Labs OY · Nov 2025
NightWatch+ US
K243199 · Livassured BV · Jul 2025
EpiMonitor
K250515 · Empatica S.R.L. · Jun 2025
EpiWatch Monitoring System
K243515 · Epiwatch, Inc. · Mar 2025
EpiMonitor
K232915 · Empatica S.R.L. · Feb 2024
SPEAC System
K200276 · Brain Sentinel, Inc. · Feb 2021